Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity.

Dijkman K, Vervenne RAW, Sombroek CC, Boot C, Hofman SO, van Meijgaarden KE, Ottenhoff THM, Kocken CHM, Haanstra KG, Vierboom MPM, Verreck FAW.

Front Immunol. 2019 Nov 1;10:2479. doi: 10.3389/fimmu.2019.02479. eCollection 2019.

2.

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells.

Tanner R, Smith SG, van Meijgaarden KE, Giannoni F, Wilkie M, Gabriele L, Palma C, Dockrell HM, Ottenhoff THM, McShane H.

J Immunol Methods. 2019 Jun;469:1-10. doi: 10.1016/j.jim.2019.01.006. Epub 2019 Jan 31.

3.

Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies.

van Meijgaarden KE, Khatri B, Smith SG, Drittij AMFH, de Paus RA, Goeman JJ, Ho MM, Dockrell HM, McShane H, Joosten SA, Ottenhoff THM.

PLoS One. 2018 Sep 4;13(9):e0201205. doi: 10.1371/journal.pone.0201205. eCollection 2018.

4.

A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer.

Bilsen MP, van Meijgaarden KE, de Jong HK, Joosten SA, Prins C, Kroft LJM, Jonker JT, Crobach S, Pelger RC, Ottenhoff THM, Arend SM.

Int J Infect Dis. 2018 Jul;72:63-68. doi: 10.1016/j.ijid.2018.05.006. Epub 2018 May 17.

5.

Mycobacterial growth inhibition is associated with trained innate immunity.

Joosten SA, van Meijgaarden KE, Arend SM, Prins C, Oftung F, Korsvold GE, Kik SV, Arts RJ, van Crevel R, Netea MG, Ottenhoff TH.

J Clin Invest. 2018 May 1;128(5):1837-1851. doi: 10.1172/JCI97508. Epub 2018 Apr 3.

6.

Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8+ T cells.

Prezzemolo T, van Meijgaarden KE, Franken KLMC, Caccamo N, Dieli F, Ottenhoff THM, Joosten SA.

Eur J Immunol. 2018 Feb;48(2):293-305. doi: 10.1002/eji.201747184. Epub 2017 Dec 15.

7.

Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis.

Rakshit S, Adiga V, Nayak S, Sahoo PN, Sharma PK, van Meijgaarden KE, Uk J AJ, Dhar C, Souza GD, Finak G, De Rosa SC, Ottenhoff THM, Vyakarnam A.

Sci Rep. 2017 Sep 20;7(1):11948. doi: 10.1038/s41598-017-10773-5.

8.

Immunological characterization of latent tuberculosis infection in a low endemic country.

de Paus RA, van Meijgaarden KE, Prins C, Kamphorst MH, Arend SM, Ottenhoff THM, Joosten SA.

Tuberculosis (Edinb). 2017 Sep;106:62-72. doi: 10.1016/j.tube.2017.07.001. Epub 2017 Jul 4.

PMID:
28802407
9.

Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression.

Coppola M, Arroyo L, van Meijgaarden KE, Franken KL, Geluk A, Barrera LF, Ottenhoff THM.

Tuberculosis (Edinb). 2017 Sep;106:25-32. doi: 10.1016/j.tube.2017.06.001. Epub 2017 Jun 8.

10.

New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.

Coppola M, van Meijgaarden KE, Franken KL, Commandeur S, Dolganov G, Kramnik I, Schoolnik GK, Comas I, Lund O, Prins C, van den Eeden SJ, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH.

Sci Rep. 2016 Nov 28;6:37793. doi: 10.1038/srep37793.

11.

Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment.

Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchini A, Petrone L, Vanini V, Smits HH, Palmieri F, Goletti D, Ottenhoff TH.

PLoS Pathog. 2016 Jun 15;12(6):e1005687. doi: 10.1371/journal.ppat.1005687. eCollection 2016 Jun.

12.

KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.

Boer MC, van Meijgaarden KE, Goletti D, Vanini V, Prins C, Ottenhoff TH, Joosten SA.

Tuberculosis (Edinb). 2016 Mar;97:163-71. doi: 10.1016/j.tube.2015.11.008. Epub 2015 Dec 8.

PMID:
26750180
13.

Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal.

Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, Kunwar CB, van Meijgaarden KE, van den Eeden SJ, Wilson L, Kabir S, Dey H, Goulart LR, Lobato J, Carvalho W, Bekele Y, Franken KL, Aseffa A, Spencer JS, Oskam L, Otttenhoff TH, Hagge DA, Geluk A.

BMC Infect Dis. 2015 Oct 28;15:477. doi: 10.1186/s12879-015-1128-0.

14.

Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

Smith SG, Smits K, Joosten SA, van Meijgaarden KE, Satti I, Fletcher HA, Caccamo N, Dieli F, Mascart F, McShane H, Dockrell HM, Ottenhoff TH; TBVI TB Biomarker Working Group.

PLoS One. 2015 Sep 14;10(9):e0138042. doi: 10.1371/journal.pone.0138042. eCollection 2015.

15.

Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults.

Boer MC, Prins C, van Meijgaarden KE, van Dissel JT, Ottenhoff TH, Joosten SA.

Clin Vaccine Immunol. 2015 Jul;22(7):778-88. doi: 10.1128/CVI.00162-15. Epub 2015 May 6.

16.

Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset.

van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA.

PLoS Pathog. 2015 Mar 24;11(3):e1004671. doi: 10.1371/journal.ppat.1004671. eCollection 2015 Mar.

17.

Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines.

Caccamo N, Pietra G, Sullivan LC, Brooks AG, Prezzemolo T, La Manna MP, Di Liberto D, Joosten SA, van Meijgaarden KE, Di Carlo P, Titone L, Moretta L, Mingari MC, Ottenhoff TH, Dieli F.

Eur J Immunol. 2015 Apr;45(4):1069-81. doi: 10.1002/eji.201445193. Epub 2015 Feb 17. Erratum in: Eur J Immunol. 2019 Jun;49(6):971.

18.

Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses.

Geluk A, van Meijgaarden KE, Joosten SA, Commandeur S, Ottenhoff TH.

Front Immunol. 2014 Jun 25;5:256. doi: 10.3389/fimmu.2014.00256. eCollection 2014. Review.

19.

Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method.

Commandeur S, Coppola M, Dijkman K, Friggen AH, van Meijgaarden KE, van den Eeden SJ, Wilson L, van der Ploeg-van Schip JJ, Franken KL, Geluk A, Ottenhoff TH.

PLoS One. 2014 Jun 6;9(6):e99203. doi: 10.1371/journal.pone.0099203. eCollection 2014.

20.

The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.

Commandeur S, van den Eeden SJ, Dijkman K, Clark SO, van Meijgaarden KE, Wilson L, Franken KL, Williams A, Christensen D, Ottenhoff TH, Geluk A.

Vaccine. 2014 Jun 17;32(29):3580-8. doi: 10.1016/j.vaccine.2014.05.005. Epub 2014 May 14.

PMID:
24837764
21.

T-cell regulation in lepromatous leprosy.

Bobosha K, Wilson L, van Meijgaarden KE, Bekele Y, Zewdie M, van der Ploeg-van Schip JJ, Abebe M, Hussein J, Khadge S, Neupane KD, Hagge DA, Jordanova ES, Aseffa A, Ottenhoff TH, Geluk A.

PLoS Negl Trop Dis. 2014 Apr 10;8(4):e2773. doi: 10.1371/journal.pntd.0002773. eCollection 2014 Apr.

22.

CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells.

Boer MC, van Meijgaarden KE, Joosten SA, Ottenhoff TH.

PLoS One. 2014 Apr 8;9(4):e94192. doi: 10.1371/journal.pone.0094192. eCollection 2014.

23.

Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions.

Geluk A, van Meijgaarden KE, Wilson L, Bobosha K, van der Ploeg-van Schip JJ, van den Eeden SJ, Quinten E, Dijkman K, Franken KL, Haisma EM, Haks MC, van Hees CL, Ottenhoff TH.

J Clin Immunol. 2014 Feb;34(2):245-55. doi: 10.1007/s10875-013-9979-x. Epub 2013 Dec 27.

PMID:
24370984
24.

CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.

Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SA.

Eur J Immunol. 2013 Jul;43(7):1925-32. doi: 10.1002/eji.201243286. Epub 2013 May 29.

25.

An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection.

Commandeur S, van Meijgaarden KE, Prins C, Pichugin AV, Dijkman K, van den Eeden SJ, Friggen AH, Franken KL, Dolganov G, Kramnik I, Schoolnik GK, Oftung F, Korsvold GE, Geluk A, Ottenhoff TH.

J Immunol. 2013 Feb 15;190(4):1659-71. doi: 10.4049/jimmunol.1201593. Epub 2013 Jan 14.

26.

A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.

Geluk A, van den Eeden SJ, van Meijgaarden KE, Dijkman K, Franken KL, Ottenhoff TH.

Vaccine. 2012 Dec 14;30(52):7513-21. doi: 10.1016/j.vaccine.2012.10.045. Epub 2012 Oct 24.

PMID:
23103299
27.

Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis.

Kassa D, Ran L, Geberemeskel W, Tebeje M, Alemu A, Selase A, Tegbaru B, Franken KL, Friggen AH, van Meijgaarden KE, Ottenhoff TH, Wolday D, Messele T, van Baarle D.

Clin Vaccine Immunol. 2012 Dec;19(12):1907-15. doi: 10.1128/CVI.00482-12. Epub 2012 Sep 26.

28.

The antimicrobial peptide hLF1-11 drives monocyte-dendritic cell differentiation toward dendritic cells that promote antifungal responses and enhance Th17 polarization.

van der Does AM, Joosten SA, Vroomans E, Bogaards SJ, van Meijgaarden KE, Ottenhoff TH, van Dissel JT, Nibbering PH.

J Innate Immun. 2012;4(3):284-92. doi: 10.1159/000332941. Epub 2012 Jan 19.

29.

T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia.

Riaño F, Arroyo L, París S, Rojas M, Friggen AH, van Meijgaarden KE, Franken KL, Ottenhoff TH, García LF, Barrera LF.

Tuberculosis (Edinb). 2012 Mar;92(2):148-59. doi: 10.1016/j.tube.2011.12.005. Epub 2012 Jan 5.

PMID:
22226907
30.

Lateral flow assay for simultaneous detection of cellular- and humoral immune responses.

Corstjens PL, de Dood CJ, van der Ploeg-van Schip JJ, Wiesmeijer KC, Riuttamäki T, van Meijgaarden KE, Spencer JS, Tanke HJ, Ottenhoff TH, Geluk A.

Clin Biochem. 2011 Oct;44(14-15):1241-6. doi: 10.1016/j.clinbiochem.2011.06.983. Epub 2011 Jul 6.

31.

Double- and monofunctional CD4⁺ and CD8⁺ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals.

Commandeur S, Lin MY, van Meijgaarden KE, Friggen AH, Franken KL, Drijfhout JW, Korsvold GE, Oftung F, Geluk A, Ottenhoff TH.

Eur J Immunol. 2011 Oct;41(10):2925-36. doi: 10.1002/eji.201141602. Epub 2011 Aug 30.

32.

Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals.

Commandeur S, van Meijgaarden KE, Lin MY, Franken KL, Friggen AH, Drijfhout JW, Oftung F, Korsvold GE, Geluk A, Ottenhoff TH.

Clin Vaccine Immunol. 2011 Apr;18(4):676-83. doi: 10.1128/CVI.00492-10. Epub 2011 Jan 19.

33.

Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis.

Tang ST, van Meijgaarden KE, Caccamo N, Guggino G, Klein MR, van Weeren P, Kazi F, Stryhn A, Zaigler A, Sahin U, Buus S, Dieli F, Lund O, Ottenhoff TH.

J Immunol. 2011 Jan 15;186(2):1068-80. doi: 10.4049/jimmunol.1002212. Epub 2010 Dec 17.

34.

Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays.

Geluk A, van der Ploeg-van Schip JJ, van Meijgaarden KE, Commandeur S, Drijfhout JW, Benckhuijsen WE, Franken KL, Naafs B, Ottenhoff TH.

Clin Vaccine Immunol. 2010 Jun;17(6):993-1004. doi: 10.1128/CVI.00046-10. Epub 2010 Apr 28.

35.

Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity.

Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, Savage ND, Drijfhout JW, Flower DR, Hanekom WA, Klein MR, Ottenhoff TH.

PLoS Pathog. 2010 Feb 26;6(2):e1000782. doi: 10.1371/journal.ppat.1000782.

36.

Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria.

Lin MY, Reddy TB, Arend SM, Friggen AH, Franken KL, van Meijgaarden KE, Verduyn MJ, Schoolnik GK, Klein MR, Ottenhoff TH.

Infect Immun. 2009 Nov;77(11):5071-9. doi: 10.1128/IAI.00457-09. Epub 2009 Sep 8.

37.

Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.

Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Franken KL, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff TH.

Vaccine. 2009 Jun 19;27(30):4010-7. doi: 10.1016/j.vaccine.2009.04.033. Epub 2009 May 3.

PMID:
19389445
38.

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination.

Lin MY, Geluk A, Smith SG, Stewart AL, Friggen AH, Franken KL, Verduyn MJ, van Meijgaarden KE, Voskuil MI, Dockrell HM, Huygen K, Ottenhoff TH, Klein MR.

Infect Immun. 2007 Jul;75(7):3523-30. Epub 2007 May 14.

39.

Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.

Joosten SA, van Meijgaarden KE, Savage ND, de Boer T, Triebel F, van der Wal A, de Heer E, Klein MR, Geluk A, Ottenhoff TH.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8029-34. Epub 2007 May 2.

40.

T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination.

Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, Klein MR.

Infect Immun. 2007 Jun;75(6):2914-21. Epub 2007 Mar 26.

41.

Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults.

Sahiratmadja E, Alisjahbana B, Buccheri S, Di Liberto D, de Boer T, Adnan I, van Crevel R, Klein MR, van Meijgaarden KE, Nelwan RH, van de Vosse E, Dieli F, Ottenhoff TH.

Tuberculosis (Edinb). 2007 Jul;87(4):312-21. Epub 2007 Mar 26.

PMID:
17382591
42.

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis.

Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, Arend SM, Ottenhoff TH, Klein MR.

Microbes Infect. 2006 Jul;8(8):2052-60. Epub 2006 Jun 13.

PMID:
16931093
43.

Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells.

Bronke C, Palmer NM, Westerlaken GH, Toebes M, van Schijndel GM, Purwaha V, van Meijgaarden KE, Schumacher TN, van Baarle D, Tesselaar K, Geluk A.

Hum Immunol. 2005 Sep;66(9):950-61. Epub 2005 Aug 16.

PMID:
16360834
44.

Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection.

Geluk A, Klein MR, Franken KL, van Meijgaarden KE, Wieles B, Pereira KC, Bührer-Sékula S, Klatser PR, Brennan PJ, Spencer JS, Williams DL, Pessolani MC, Sampaio EP, Ottenhoff TH.

Infect Immun. 2005 Sep;73(9):5636-44.

45.

Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis.

Bivas-Benita M, van Meijgaarden KE, Franken KL, Junginger HE, Borchard G, Ottenhoff TH, Geluk A.

Vaccine. 2004 Apr 16;22(13-14):1609-15.

PMID:
15068842
46.

Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis.

Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR, Naafs B, Ottenhoff TH.

Scand J Immunol. 2004 Jan;59(1):66-70.

47.

Interferon-gamma production in response to M. tuberculosis antigens in TB patients in Indonesia.

Subronto YW, van Meijgaarden KE, Geluk A, Arend SM, Sunardi T, Franken KL, Hisyam B, de Vries RR, Ottenhoff TH.

Adv Exp Med Biol. 2003;531:249-60. No abstract available.

PMID:
12916797
48.

Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii.

Arend SM, van Meijgaarden KE, de Boer K, de Palou EC, van Soolingen D, Ottenhoff TH, van Dissel JT.

J Infect Dis. 2002 Dec 15;186(12):1797-807. Epub 2002 Nov 19.

PMID:
12447766
49.

Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis.

Geluk A, van Meijgaarden KE, Franken KL, Subronto YW, Wieles B, Arend SM, Sampaio EP, de Boer T, Faber WR, Naafs B, Ottenhoff TH.

Infect Immun. 2002 May;70(5):2544-8.

50.

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R.

Cancer Res. 2002 Jan 15;62(2):472-9.

Supplemental Content

Loading ...
Support Center